Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
The expiration date on the vial label is the documented endpoint for sealed storage under the specified temperature conditions
Store in a cool, dry and stable environment
3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
Va de administracin: Subcutnea o intramuscular
The standard AOD 9604 dosage in clinical use is 250500 mcg, administered subcutaneously once every morning on an empty stomach, and cycled in 412-week blocks
US$ 27.93
US$ 24.52
US$ 22.41
US$ 23.16
US$ 20.89
